-
RIPA Lysis Buffer (Medium): Build a Causal Evidence Chain
2026-09-21
RIPA Lysis Buffer (Medium) can convert complex cell and tissue responses into interpretable protein evidence. This guide shows how its detergent chemistry, inhibitor strategy, and assay-specific controls can strengthen mechanistic analysis of MRSA extracellular-vesicle signaling in oral cancer models.
-
CUDC-907: Dual PI3K/HDAC Workflow Guide
2026-09-21
CUDC-907 is a dual PI3K and HDAC inhibitor for controlled in vitro studies of signaling, acetylation, cell-cycle behavior, and apoptosis. This guide uses product-dossier specifications and practical laboratory recommendations; the compound is for scientific research only and should not be used for diagnosis, treatment, or clinical decision-making.
-
Doxorubicin Hydrochloride: Assays & Cardiotoxicity
2026-09-20
Build reproducible cancer chemotherapy research and cardiotoxicity workflows with Doxorubicin hydrochloride, from dose–response and apoptosis assays to mechanistic energy-stress studies. A practical workflow connects Adriamycin HCl exposure with the emerging KLF16–ATF4–CSE/H2S antioxidation axis while separating established evidence from assay-development recommendations.
-
Methotrexate Workflows for Immunology Research
2026-09-19
Build reproducible Methotrexate experiments around DHFR inhibition, exposure timing, and orthogonal readouts of cytostasis, apoptosis, and inflammation. This workflow distinguishes direct cellular effects from vehicle, folate-state, and assay-timing artifacts while connecting bench immunology to clinically relevant mechanisms.
-
GLI2–PRDX1 Axis Drives Ferroptosis Resistance
2026-09-18
The 2026 reference study identifies GLI2 as a transcriptional driver of ferroptosis resistance in bladder cancer through upregulation of PRDX1. Its perturbation, chromatin, transcriptomic, and rescue experiments connect this axis to malignant progression and cisplatin sensitivity, providing a mechanistic framework for chemotherapy-oriented cancer research.
-
Ibotenic Acid: NMDA Agonist Workflow Guide
2026-09-18
This practical guide shows how to use Ibotenic acid as a controlled neuroscience research tool for glutamatergic signaling studies, neurotoxicity profiling, and neurodegenerative disease model development. It translates recent dose- and time-dependent mouse findings into assay planning, sample handling, and troubleshooting decisions.
-
Amyloid β-Peptide (1-42): Microglial Assays
2026-09-17
Use Amyloid β-Peptide (1-42) to build two complementary Alzheimer’s disease models: a neuronal injury assay and a microglial migration, uptake, and clearance workflow. The key advantage is mechanistic resolution—aggregation state, extracellular nucleotide signaling, and P2Y2-dependent Aβ42 handling can be tested separately rather than treated as one nonspecific toxicity endpoint.
-
Palonosetron and Chemotherapy-Induced Nausea
2026-09-17
Ruhlmann and Herrstedt’s drug profile examines whether palonosetron’s distinctive receptor pharmacology translates into better prevention of chemotherapy-induced nausea and vomiting than earlier 5-HT3 antagonists. Its practical contribution is a structured comparison of preclinical evidence, registration trials, and post-registration experience, with particular attention to acute versus delayed symptoms, nausea control, and tolerability.
-
Dacarbazine in Cancer Response Assays
2026-09-16
Use Dacarbazine to model DNA-damaging chemotherapy in malignant melanoma, Hodgkin lymphoma, and sarcoma research while separating growth arrest from true cell killing. This workflow combines controlled exposure, orthogonal viability measurements, and time-aware interpretation to produce more informative response profiles than a single endpoint.
-
Cholesterol Workflows for mRNA-LNP Research
2026-09-16
Learn how Cholesterol supports reproducible lipid nanoparticle assembly, membrane fluidity assays, and localized mRNA delivery research. This workflow translates bladder cancer findings into practical formulation, quality-control, and troubleshooting steps while distinguishing published evidence from experimental starting points.
-
VX-661: F508del CFTR Corrector Guide
2026-09-15
VX-661 is a small-molecule F508del CFTR corrector that supports mutant CFTR folding, trafficking, and cell-surface expression. Its correction activity differs from VX-770 potentiation and depends on assay conditions, variant context, and cellular proteostasis.
-
Mitoxantrone HCl: DNA Damage Assay Workflows
2026-09-15
Build reproducible DNA-damage, apoptosis, and cell-viability experiments with Mitoxantrone HCl while separating canonical Topo-II effects from emerging ERα allosteric activity. Practical preparation guidance, assay controls, and troubleshooting help translate this compound into leukemia, stem-cell, multiple sclerosis, and solid-tumor research workflows.
-
SARS-CoV-2 Release Factors Revealed by RNAi Screening
2026-09-14
Kerr et al. developed an arrayed, druggable-genome RNA interference screen that measured SARS-CoV-2 production at multiple stages, helping identify host factors involved beyond early replication. The study highlights Rab11a-mediated vesicular transport and CDK9-linked cargo delivery as experimentally supported determinants of viral release, while also defining important boundaries for translating kinase-inhibitor findings into antiviral research.
-
Topological Stress and PML-Nucleolar Compartments
2026-09-14
Urbancokova and colleagues show that persistent ribosomal DNA lesions, rather than generic genotoxic stress alone, drive PML-nucleolar compartment formation through topological stress, RNA polymerase I inhibition, and incomplete homologous recombination. The study provides a mechanistic framework for connecting rDNA damage with nucleolar reorganization, cellular senescence, genome instability, and cancer biology.
-
CIP2A–PKM2 Drives Oxidative Phosphorylation in NSCLC
2026-09-13
The reference study identifies CIP2A as a metabolic regulator that shifts NSCLC cells from glycolysis toward oxidative phosphorylation by promoting PKM2 tetramer formation and mitochondrial localization. Its findings connect PKM2 serine 287 phosphorylation, Bcl2 signaling, and tumor-cell fitness, while supporting combined targeting of CIP2A and glycolysis as a research strategy.